Dr. Reddy's Launches BixiBat (Elobixibat) as First-in-Class Drug for Chronic Constipation in India
Key Insights
Dr. Reddy's Laboratories has launched BixiBat (search), a first-in-class drug containing Elobixibat, for treating chronic constipation (search) in India, following approval from the CDSCO.
Elobixibat inhibits bile acid reabsorption in the ileum, increasing their concentration in the colon, which stimulates colonic motility and fluid secretion to promote bowel movements.
Clinical studies have demonstrated that BixiBat (search) shows significantly better outcomes, marking it as a potential breakthrough in managing chronic constipation (search) and improving the standard of care.
Dr. Reddy's Laboratories has announced the launch of BixiBat (search) in India, a drug containing Elobixibat, hailed as a first-in-class treatment for chronic constipation (search). The Hyderabad-based pharmaceutical firm received approval from the Central Drugs Standard Control Organisation (CDSCO) to market the drug.
Elobixibat's mechanism of action involves inhibiting the reabsorption of bile acids (search) in the ileum. This increases the concentration of bile acids in the colonic lumen, leading to stimulation of both colonic motility and fluid secretion, ultimately promoting bowel movements regardless of transit speed.
"The launch of this first-in-class drug is the latest in our continued efforts to bring novel molecules to patients in India," said Dr. Reddy's CEO Branded Markets (India and Emerging Markets) MV Ramana. He further added, "The clinical studies for BixiBat (search) have demonstrated significantly better and promising outcomes, making it a breakthrough drug in the management of chronic constipation (search) and enhancing the current standard of care for its treatment in India."
The introduction of BixiBat (search) represents a significant advancement in the treatment of chronic constipation (search), offering a novel approach to managing the condition and potentially improving the quality of life for patients in India.